| First Author | Song Y | Year | 2024 |
| Journal | Brain Behav Immun | Volume | 122 |
| Pages | 185-201 | PubMed ID | 39142420 |
| Mgi Jnum | J:353405 | Mgi Id | MGI:7714283 |
| Doi | 10.1016/j.bbi.2024.08.028 | Citation | Song Y, et al. (2024) A pentavalent peptide vaccine elicits Abeta and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model. Brain Behav Immun 122:185-201 |
| abstractText | Amyloid-beta (Abeta) and hyperphosphorylated tau protein are targets for Alzheimer's Disease (AD) immunotherapies, which are generally focused on single epitopes within Abeta or tau. However, due to the complexity of both Abeta and tau in AD pathogenesis, a multipronged approach simultaneously targeting multiple epitopes of both proteins could overcome limitations of monotherapies. Herein, we propose an active AD immunotherapy based on a nanoparticle vaccine comprising two Abeta peptides (1-14 and pyroglutamate pE3-14) and three tau peptides (centered on phosphorylated pT181, pT217 and pS396/404). These correspond to both soluble and aggregated targets and are displayed on the surface of immunogenic liposomes in an orientation that maintains reactivity with epitope-specific monoclonal antibodies. Intramuscular immunization of mice with individual epitopes resulted in minimally cross-reactive antibody induction, while simultaneous co-display of 5 antigens ("5-plex") induced antibodies against all epitopes without immune interference. Post-immune sera recognized plaques and neurofibrillary tangles from human AD brain tissue. Vaccine administration to 3xTg-AD mice using a prophylactic dosing schedule inhibited tau and amyloid pathologies and resulted in improved cognitive function. Immunization was well tolerated and did not induce antigen-specific cellular responses or persistent inflammatory responses in the peripheral or central nervous system. Antibody levels could be reversed by halting monthly vaccinations. Altogether, these results indicate that active immune therapies based on nanoparticle formulations of multiple Abeta and tau epitopes warrant further study for treating early-stage AD. |
